Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSCAR first-line hepatic-only metastatic colorectal cancer trial
2024-518553-41-00Phase 3Authorised
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Nov 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in colorectal adenocarcinoma and colorectal cancer (CRC) (4 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Radiological and/or clinical progression-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
oxaliplatin
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-518553-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518553-41-00.